SLC4A7 suppresses lung adenocarcinoma oncogenesis by reducing lactate transport and protein lactylation
International Journal of Oncology · 2025
DOI: 10.3892/ijo.2025.5739 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Oncology, 2025. Verfasst von Haojie Yan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Translational Medicine Collaborative Innovation Center, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University; The Firs…. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung, Lactic Acid, Sodium-Bicarbonate Symporters. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Lactate and protein lactylation serve a key role in tumor pathogenesis. Solute carrier 4A7 (SLC4A7), a key transporter, participates in cellular acid homeostasis. However, its impact on lactate transport and protein lactylation in solid tumors, particularly lung adenocarcinoma (LUAD), remains largely unexplored. In the present study, lactylome analysis, Transwell and wound healing assay, animal experiments were conducted to validate functional regulation mediated by SLC4A7 in LUAD. SLC4A7 inhibited tumor progression, including metastasis, invasion and proliferation. Mechanistically, SLC4A7 decreased both intracellular and extracellular lactate accumulation and inhibited overall protein lactylation, as confirmed by lactylome analysis. Analyzing the lactylome revealed that SLC4A7 suppressed lysine lactylation of numerous genes like HSP90AA1 and pathways such as focal adhesion associated with carcinogenesis. Additionally, low expression levels of SLC4A7 in LUAD cancer stem cells were validated using tumor tissue samples from patients with LUAD. Moreover, the inhibitory role of SLC4A7 in regulating tumor stemness was verified. Collectively, the present results uncovered the inhibitory effect exerted by SLC4A7 on tumor progression via its regulation of lactate transport, protein lactylation and stemness properties. Targeting SLC4A7 may hold promise as a novel therapeutic strategy for LUAD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Medicine Collaborative Innovation Center, Shenzhen People's Hospital (The Second Clinical Medical College of Jinan University; The First Affiliated Hospital, Southern University of Science and Technology),…
- Post‑doctoral Scientific Research Station of Basic Medicine, Jinan University, Guangzhou, Guangdong 510632, P.R. China.
Zitieren
APA
Yan, H., He, Q., Gao, Y., He, X., Luo, H., Shao, L., Dong, J., & Li, F. (2025). SLC4A7 suppresses lung adenocarcinoma oncogenesis by reducing lactate transport and protein lactylation. International Journal of Oncology. https://doi.org/10.3892/ijo.2025.5739
Vancouver
Yan H, He Q, Gao Y, He X, Luo H, Shao L, et al. SLC4A7 suppresses lung adenocarcinoma oncogenesis by reducing lactate transport and protein lactylation. International Journal of Oncology. 2025. doi:10.3892/ijo.2025.5739
BibTeX
@article{Yan2025,
author = {Yan, Haojie and He, Qian and Gao, Yubiao and He, Xiaomei and Luo, Haitao and Shao, Lijuan and Dong, Jun and Li, Furong},
title = {SLC4A7 suppresses lung adenocarcinoma oncogenesis by reducing lactate transport and protein lactylation},
journal = {International Journal of Oncology},
year = {2025},
doi = {10.3892/ijo.2025.5739}
}
EUVIMED